KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Gains from Equity Investments (2016 - 2018)

Historic Gains from Equity Investments for Inovio Pharmaceuticals (INO) over the last 10 years, with Q3 2018 value amounting to -$228665.0.

  • Inovio Pharmaceuticals' Gains from Equity Investments rose 4597.99% to -$228665.0 in Q3 2018 from the same period last year, while for Jun 2019 it was -$228665.0, marking a year-over-year increase of 7985.28%. This contributed to the annual value of -$360795.0 for FY2018, which is 5528.18% up from last year.
  • As of Q3 2018, Inovio Pharmaceuticals' Gains from Equity Investments stood at -$228665.0, which was up 4597.99% from -$259971.0 recorded in Q2 2018.
  • Inovio Pharmaceuticals' Gains from Equity Investments' 5-year high stood at $505926.0 during Q1 2014, with a 5-year trough of -$824390.0 in Q2 2014.
  • Moreover, its 5-year median value for Gains from Equity Investments was -$2691.0 (2016), whereas its average is -$95835.4.
  • In the last 5 years, Inovio Pharmaceuticals' Gains from Equity Investments soared by 3326340.67% in 2016 and then plummeted by 1563006.32% in 2017.
  • Inovio Pharmaceuticals' Gains from Equity Investments (Quarter) stood at -$143659.0 in 2014, then soared by 302.09% to $290316.0 in 2015, then plummeted by 322.13% to -$644888.0 in 2016, then increased by 10.13% to -$579546.0 in 2017, then soared by 60.54% to -$228665.0 in 2018.
  • Its Gains from Equity Investments was -$228665.0 in Q3 2018, compared to -$259971.0 in Q2 2018 and $127841.0 in Q1 2018.